Summary of Study ST000138

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000123. The data can be accessed directly via it's Project DOI: 10.21228/M8PC7J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Study ID	ST000138
Study Title	Targeted LC MS of acylcarnitines: TLCMS
Study Summary	Acylcarnitines (panel of 66 quantitated acylcarnitines) analyzed by LC/MS/MS using flow injection analysis with electrospray ionization
Institute	University of Florida
Department	Pharmacotherapy and Translational Research
Last Name	Cooper-DeHoff
First Name	Rhonda
Email	dehoff@cop.ufl.edu
Submit Date	2015-01-08
Raw Data Available	Yes
Raw Data File Type(s)	d
Uploaded File Size	1.3 G
Analysis Type Detail	LC-MS
Release Date	2016-06-18
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000123
Project DOI:	doi: 10.21228/M8PC7J
Project Title:	A targeted pharmacometabolomic investigation of the acylcarnitine pathway and incident impaired fasting glucose (IFG)
Institute:	University of Florida
Department:	Pharmacotherapy and Translational Research
Last Name:	Cooper-DeHoff
First Name:	Rhonda
Email:	dehoff@cop.ufl.edu

Subject:

Subject ID:	SU000157
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Human Inclusion Criteria:	Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG.
Human Exclusion Criteria:	Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study.
Species Group:	Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	Gender
SA007499	PE0077	f \| Race:asian
SA007500	PE0005	f \| Race:black
SA007501	PE0403	f \| Race:black
SA007502	PE0380	f \| Race:black
SA007503	PF0436	f \| Race:black
SA007504	PE0358	f \| Race:black
SA007505	PE0422	f \| Race:black
SA007506	PE0423	f \| Race:black
SA007507	PE0488	f \| Race:black
SA007508	PE0492	f \| Race:black
SA007509	PE0455	f \| Race:black
SA007510	PE0438	f \| Race:black
SA007511	PE0433	f \| Race:black
SA007512	PE0346	f \| Race:black
SA007513	PE0332	f \| Race:black
SA007514	PE0251	f \| Race:black
SA007515	PE0268	f \| Race:black
SA007516	PE0243	f \| Race:black
SA007517	PE0240	f \| Race:black
SA007518	PE0224	f \| Race:black
SA007519	PE0285	f \| Race:black
SA007520	PF0463	f \| Race:black
SA007521	PF0448	f \| Race:black
SA007522	PE0330	f \| Race:black
SA007523	PE0317	f \| Race:black
SA007524	PE0310	f \| Race:black
SA007525	PE0292	f \| Race:black
SA007526	PE0494	f \| Race:black
SA007527	PR0449	f \| Race:black
SA007528	PF0093	f \| Race:black
SA007529	PF0146	f \| Race:black
SA007530	PF0080	f \| Race:black
SA007531	PF0079	f \| Race:black
SA007532	PF0078	f \| Race:black
SA007533	PF0156	f \| Race:black
SA007534	PF0165	f \| Race:black
SA007535	PF0184	f \| Race:black
SA007536	PF0201	f \| Race:black
SA007537	PF0181	f \| Race:black
SA007538	PF0228	f \| Race:black
SA007539	PF0169	f \| Race:black
SA007540	PR0300	f \| Race:black
SA007541	PF0305	f \| Race:black
SA007542	PE0536	f \| Race:black
SA007543	PE0540	f \| Race:black
SA007544	PE0517	f \| Race:black
SA007545	PF0357	f \| Race:black
SA007546	PF0361	f \| Race:black
SA007547	PF0020	f \| Race:black
SA007548	PF0330	f \| Race:black
SA007549	PF0060	f \| Race:black
SA007550	PF0048	f \| Race:black
SA007551	PF0315	f \| Race:black
SA007552	PF0044	f \| Race:black
SA007553	PE0219	f \| Race:black
SA007554	PE0331	f \| Race:black
SA007555	PF0528	f \| Race:black
SA007556	PE0114	f \| Race:black
SA007557	PE0216	f \| Race:black
SA007558	PF0543	f \| Race:black
SA007559	PE0086	f \| Race:black
SA007560	PE0092	f \| Race:black
SA007561	PF0524	f \| Race:black
SA007562	PE0128	f \| Race:black
SA007563	PE0143	f \| Race:black
SA007564	PE0148	f \| Race:black
SA007565	PF0507	f \| Race:black
SA007566	PE0138	f \| Race:black
SA007567	PE0137	f \| Race:black
SA007568	PE0072	f \| Race:black
SA007569	PE0071	f \| Race:black
SA007570	PE0037	f \| Race:black
SA007571	PE0040	f \| Race:black
SA007572	PE0032	f \| Race:black
SA007573	PE0028	f \| Race:black
SA007574	PE0019	f \| Race:black
SA007575	PE0022	f \| Race:black
SA007576	PE0042	f \| Race:black
SA007577	PE0045	f \| Race:black
SA007578	PE0064	f \| Race:black
SA007579	PE0068	f \| Race:black
SA007580	PE0062	f \| Race:black
SA007581	PE0059	f \| Race:black
SA007582	PE0055	f \| Race:black
SA007583	PE0149	f \| Race:black
SA007584	PF0539	f \| Race:black
SA007585	PE0188	f \| Race:black
SA007586	PE0186	f \| Race:black
SA007587	PE0181	f \| Race:black
SA007588	PE0172	f \| Race:black
SA007589	PE0191	f \| Race:black
SA007590	PE0196	f \| Race:black
SA007591	PE0205	f \| Race:black
SA007592	PE0203	f \| Race:black
SA007593	PF0494	f \| Race:black
SA007594	PE0169	f \| Race:black
SA007595	PE0187	f \| Race:black
SA007596	PE0161	f \| Race:black
SA007597	PE0168	f \| Race:black
SA007598	PF0424	f \| Race:black_hisp

Showing page 1 of 4 Results: 1 2 3 4 Next Showing results 1 to 100 of 370

Collection:

Collection ID:	CO000141
Collection Summary:	At baseline and after completion of atenolol treatment, blood samples were collected and spun. Serum and plasma fractions were stored at -80C. 200 uL of plasma were aliquoted for metabolomics analyses. Sample Type: Blood serum Volume Collected: 200 uL
Sample Type:	Blood

Treatment:

Treatment ID:	TR000159
Treatment Summary:	Atenolol was initiated at 50mg, and titrated to 100mg, based on BP > 120/70 mmHg and tolerability. Blood samples were collected prior to initiation of atenolol treatment and after at least 6 weeks on the final dose. Blood samples were spun and serum and plasma fractions stored at -80C. Treatment: Intervention Treatment Compound: Atenolol Treatment Dose: 50mg titrated to 100mg based on BP and tolerability Treatment Dose Duration: Minimum of 6 weeks

Treatment ID:

TR000159

Treatment Summary:

Atenolol was initiated at 50mg, and titrated to 100mg, based on BP > 120/70 mmHg and tolerability. Blood samples were collected prior to initiation of atenolol treatment and after at least 6 weeks on the final dose. Blood samples were spun and serum and plasma fractions stored at -80C. Treatment: Intervention Treatment Compound: Atenolol Treatment Dose: 50mg titrated to 100mg based on BP and tolerability Treatment Dose Duration: Minimum of 6 weeks

Sample Preparation:

Sampleprep ID:	SP000154
Sampleprep Summary:	-
Sampleprep Protocol Filename:	Acylcarnitines_LCMSProtocol_SBMRI_ForSECIM_111714.docx

Combined analysis:

Analysis ID	AN000220
Analysis type	MS
Chromatography type	Reversed phase
Chromatography system	Agilent 1290 Infinity
Column	Waters Acquity BEH C18 (100 x 2mm,1.7um)
MS Type	ESI
MS instrument type	Triple quadrupole
MS instrument name	Agilent 6490 QQQ
Ion Mode	POSITIVE
Units	uM

Chromatography:

Chromatography ID:	CH000152
Instrument Name:	Agilent 1290 Infinity
Column Name:	Waters Acquity BEH C18 (100 x 2mm,1.7um)
Chromatography Type:	Reversed phase

MS:

MS ID:	MS000171
Analysis ID:	AN000220
Instrument Name:	Agilent 6490 QQQ
Instrument Type:	Triple quadrupole
MS Type:	ESI
Ion Mode:	POSITIVE